Title Financial News -- LegoChem, ready to become a R&D specialized pharmaceutical company

Publication: Financial News / Byeong Jeong Yhe

Date: 03 April 2013

Summary

• In May, the first KOSAQ IPO company is coming out from the Business Incubator Center run by Daejeon.

• CEO of LegoChem Bioscience, Yong Zu Kim, was invited to present the Oxazolidinone antibiotics for the world’s largest Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

• Dr. Kim played a major part in the Korea's first licensing-out deal in 1991with GlaxoSmithKline, a British pharmaceutical company.

• Former success became a good stepping stone to sign the deal with AstraZeneca for joint research and license-out of new antibiotics that treat super bacteria resistant to existing antibiotics.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).